title: Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells.
authors.forename: D K
authors.initials: DK
authors.lastname: Hiwase
authors.forename: D L
authors.initials: DL
authors.lastname: White
authors.forename: V A
authors.initials: VA
authors.lastname: Saunders
authors.forename: S
authors.initials: S
authors.lastname: Kumar
authors.forename: J V
authors.initials: JV
authors.lastname: Melo
authors.forename: T P
authors.initials: TP
authors.lastname: Hughes
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D016923:Cell Death; D045744:Cell Line, Tumor; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D018922:HL-60 Cells; D006801:Humans; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D011743:Pyrimidines / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib